EUVIMEDEUVIMED entdecken
Open Access

Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy

Hwan Lee, Swarbhanu Sarkar, Kexiang Xu, Paul Martorano, Jonathan Pham, Peter Sang Uk Park, A Paden King, Hsiaoju S Lee, David A Mankoff, Daniel A Pryma, Mark A Sellmyer

Journal of Nuclear Medicine · 2026-03 · 67 (3) · 429-437

DOI: 10.2967/jnumed.125.270175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 30.12.2025. Verfasst von Hwan Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Alpha Particles, Astatine, Molecular Targeted Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIBIB NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted α-therapy (TAT) is a promising approach for radiopharmaceutical therapy with various molecular targets, but uncertainty exists as to whether the subcellular location of a target influences its cytotoxicity. We used a model system that provides a subcellular "zip code" for TAT to determine whether localizing α-emitters closer to the DNA increases their cytotoxic effect.

Methods

Human pleural mesothelioma (I45) and ovarian adenocarcinoma (SKOV3) cell lines were engineered to express a fusion Escherichia coli dihydrofolate reductase-yellow fluorescent protein localized to the DNA, nucleus, cytoplasm, and plasma membrane. Subcellular TAT was achieved by targeting Escherichia coli dihydrofolate reductase with [211At]At-trimethoprim (TMP), an analog of the antibiotic TMP labeled with α-emitting 211At. This model system was characterized using confocal microscopy, flow cytometry, and radioligand binding assays. In vitro cytotoxicity of subcellular [211At]At-TMP therapy was measured, followed by Monte Carlo subcellular dosimetry. In vivo biodistribution and antitumor efficacy of [211At]At-TMP were measured. Results: [211At]At-TMP targeted at the DNA, followed by the nucleus, yielded the highest in vitro cytotoxicity per 211At decay. The cytotoxic advantage persisted even after normalizing to α-particle nuclear dose deposition using subcellular dosimetry, suggesting a significant cytotoxic contribution by the α-recoil, which is not considered in standard subcellular dosimetry calculations. Targeting of the plasma membrane caused at least comparable cytotoxicity to cytoplasmic targeting, suggesting a potential role of membrane damage-induced cytotoxicity. In vivo xenografts responded similarly to nuclear versus cytoplasmic [211At]At-TMP, supported by subcellular dosimetry that predicted the relevance of subcellular TAT for the treatment of individual tumor cells and small tumor cell clusters.

Conclusion

An α-emitter's proximity to the DNA yields higher cytotoxicity, which can guide future TAT drug development for improved treatment of microscopic metastases in addition to macroscopic disease, potentially leading to better clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesAstatineMolecular Targeted TherapyHumansAnimalsCell Line, TumorMiceFemaleTetrahydrofolate DehydrogenaseTissue DistributionRadiopharmaceuticals

Stichwörter der Autor:innen

cytotoxicitysubcellular localizationtargeted α-therapy

Substanzen

AstatineAstatine-211Tetrahydrofolate DehydrogenaseRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; and.
  • Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; mark.sellmyer@pennmedicine.upenn.edu.
  • Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania.

Förderung

  • NIGMS NIH HHS
  • NIBIB NIH HHS
  • NIH HHS

Zitieren

APA

Lee, H., Sarkar, S., Xu, K., Martorano, P., Pham, J., Park, P. S. U., King, A. P., Lee, H. S., Mankoff, D. A., Pryma, D. A., & Sellmyer, M. A. (2026). Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy. Journal of Nuclear Medicine, 67(3), 429-437. https://doi.org/10.2967/jnumed.125.270175

Vancouver

Lee H, Sarkar S, Xu K, Martorano P, Pham J, Park PSU, et al. Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy. Journal of Nuclear Medicine. 2026;67(3):429-437. doi:10.2967/jnumed.125.270175

BibTeX
@article{Lee2026,
  author = {Lee, Hwan and Sarkar, Swarbhanu and Xu, Kexiang and Martorano, Paul and Pham, Jonathan and Park, Peter Sang Uk and King, A Paden and Lee, Hsiaoju S and Mankoff, David A and Pryma, Daniel A and Sellmyer, Mark A},
  title = {Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {429--437},
  doi = {10.2967/jnumed.125.270175}
}
Kostenlos starten →